Notifications
Back

Leadership

Three co-founders, unrivaled scientific capability

In-San Kim

Co-Founder / MD. Ph.D.
Founding Visionary and Principal Technologist

  • MD. and Ph.D. from Kyungpook National University School of Medicine
  • Cancer research at M.D. Anderson Cancer Center
  • KIST Fellow Researcher
  • Professor at KU-KIST Graduate School
  • Expertise in Cancer Immunology and NNP Therapy
  • Published over 400 papers (h-index: 89)

Gi-Hoon Nam

Co-Founder / MD. Ph.D.
Chief Executive Officer

  • MD. from Korea University School of Medicine
  • Ph.D. from KU-KIST Graduate School
  • Professor at Korea University Medical of College
  • Research on Cancer Immunotherapy and NNP engineering at KIST and Harvard Medical School

Won-Yong Lee

Co-Founder / MD. Ph.D.
Chief Executive Officer

  • MD. from Seoul National University School of Medicine
  • Ph.D. from Sungkyunkwan University
  • Otolaryngologist, Head and Neck Surgery training at Samsung Medical Center
  • Clinical Fellow, Seoul National University Hospital
  • Professor at Busan National University

Meet the TEAM


Team SHIFTBIO

is demonstrating the best teamwork
for a common goal.

We respect the capabilities
that each individual can demonstrate

and the synergy effect created
through cooperation.

More

For successful drug development
We are organizing the Scientific Advisory Board(SAB)
by consulting with authorities in each field
and discussing with renowned experts around the world.

Drug Development Research

Thomas M. Roberts, PhD.
  • Former Chairman, Department of Cancer Biology at the Dana-Farber Cancer Institute 
  • Former Dean of Graduate Education at Harvard Medical School

Contributing to the research of Ciba-Geigy, Key role in the development of Gleevec, which is one of the first molecularly-targeted cancer therapies. 


 Natural Nanoparticle (NNP) Research

Kenneth Whitaker Witwer, PhD.
  • Associate Professor, Johns Hopkins University School of Medicine
  • President, International Society for Extracellular Vesicles

World-class scientist in NNPs 

Biomarker Research

Dolores Di Vizio, MD, PhD. 
  • Professor, Cedars-Sinai, Pathology and Laboratory Medicine 
  • Co-Leader, Cancer Biology Program, Cedars-Sinai, Cancer Institute 
  • Senior Advisor, International Society of Extracellular Vesicles

World-class scientist in circulating NNPs

For successful drug development
We are organizing
the Scientific Advisory Board(SAB)
by consulting with authorities in each field
and discussing with renowned experts around the world.

Drug Development Research

Thomas M. Roberts, PhD.
  • Former Chairman, Department of Cancer Biology at the Dana-Farber Cancer Institute 
  • Former Dean of Graduate Education at Harvard Medical School

Contributing to the research of Ciba-Geigy, Key role in the development of Gleevec, which is one of the first molecularly-targeted cancer therapies. 


 Natural Nanoparticle (NNP) Research

Kenneth Whitaker Witwer, Ph.D.
  • Associate Professor, Johns Hopkins University School of Medicine
  • President, International Society for Extracellular Vesicles

World-class scientist in NNPs 


Biomarker Research

Dolores Di Vizio, MD, PhD. 
  • Professor, Cedars-Sinai, Pathology and Laboratory Medicine 
  • Co-Leader, Cancer Biology Program, Cedars-Sinai, Cancer Institute 
  • Senior Advisor, International Society of Extracellular Vesicles 

World-class scientist in circulating NNPs